Q3 2020 sales growth(2) driven by strong Dupixent® and flu vaccines demand.
- Net sales were €9,479 million, up 5.7%(2) at CER and down 0.2% on a reported basis.
- Specialty Care sales grew 23.8%, driven by strong Dupixent® performance (+68.6% to €918 million) and growth in all franchises.
- Vaccines sales up 13.6%, driven by record flu sales partly offset by decline in boosters, travel and Menactra® due to COVID-19.
- General Medicines sales single-digit decline (-6.4%), reflecting China VBP program and U.S. Diabetes.
- CHC sales down 1.1% due to Zantac® voluntary recall in October 2019 and lower in-person pharmacy traffic in Rest of the World.
Q3 2020 business EPS(1) growth at CER driven mainly by strong sales performance and efficiencies.
- Q3 2020 business net income was up 1.0% on a reported basis to €2,299 million and increased 9.4% at CER.
- Q3 2020 business EPS(1) was €1.83, up 0.5% on a reported basis and 8.8% at CER.
- Q3 2020 IFRS EPS was €1.55.
Delivering on R&D
- Adding seven new Phase 3 programs to our oncology and immunology pipelines.
- COVID-19 adjuvanted recombinant protein-based vaccine Phase 1/2 trial fully enrolled.
- Principia acquisition brings full ownership of brain-penetrant BTKi tolebrutinib and innovative BTKi platform.
2020 business EPS(1) guidance revised upward
• Sanofi now expects 2020 business EPS(1) to grow between 7% and 8%(3) at CER, barring unforeseen major adverse events. Applying average October 2020 exchange rates, the currency impact on 2020 business EPS is estimated to be between -6% to -7%.
Sanofi Chief Executive Officer, Paul Hudson, commented:
“We achieved a strong quarter supported by solid sales from both Dupixent® and Vaccines which allows us to upgrade our full year guidance. We remain focused on executing on our strategic priorities that will deliver promising medicines to address significant patient needs. To this end, we strengthened our R&D pipeline with the successful completion of the Principia acquisition, adding multiple BTK inhibitors to address a variety of serious illnesses. Our COVID-19 vaccines development efforts continue on a fast track along with ensuring global access with pre-orders signed with major countries, regions, and non-profit organizations who will work to distribute the vaccine to those who most need it.”
